middle.news

BCAL Secures Exclusive Rights for Early Pancreatic and Ovarian Cancer Blood Tests in Australia

10:31am on Thursday 18th of September, 2025 AEST Healthcare
Read Story

BCAL Secures Exclusive Rights for Early Pancreatic and Ovarian Cancer Blood Tests in Australia

10:31am on Thursday 18th of September, 2025 AEST
Key Points
  • Exclusive licence agreement with ClearNote Health for Avantect pancreatic and ovarian cancer tests
  • Tests to be integrated into BCAL’s existing Australian and New Zealand medical networks
  • Agreement initially for two years with option to extend six years
  • Tests leverage ClearNote’s epigenomics platform with high sensitivity and specificity
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about BDX
OPEN ARTICLE